Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates

Blood

Volumn 101, Issue 6, 2003, Pages 2199-2205

  Hematti, Peiman ^a   Sellers, Stephanie E ^a   Agricola, Brian A ^a   Metzger, Mark E ^a   Donahue, Robert E ^a   Dunbar, Cynthia E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BONE MARROW; CONTROLLED STUDY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0037443484     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2663     Document Type: Article

References (56)

1. Van Beusechem VW, Valerio D. Gene transfer into hematopoietic stem cells of nonhuman primates. Hum Gene Ther. 1996;7:1649-1668.
2. Kiem HP, Andrews RG, Morris J, et al. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood. 1998;92:1878-1886.
3. Wu T, Kim HJ, Sellers SE, et al. Prolonged high-level detection of retrovirally marked hematopoietic cells in non-human primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther. 2000;1:285-293.
4. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.
5. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185-1193.
6. Hoogerbrugge PM, Vossen JM, Van Beusechem VW, Valerio D. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells. Hum Gene Ther. 1992;3:553-558.
7. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet. 1993;341:85-86.
8. Dunbar CE, Cottler-Fox M, O'Shaughnessy J, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 1995;85:3048-3057.
9. Hoogerbrugge PM, Van Beusechem VW, Fisher A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 1996;3:179-183.
10. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296:2410-2413.
11. Malech HL, Maples PB, Whiting-Theobald N,et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A. 1997;94:12133-12138.
12. Liu JM, Kim S, Read EJ, et al. Engraftment of matopoietic progenitor cells transduced with the Fanconi Anemia Group C gene (FANCC). Hum Gene Ther. 1999;10:2337-2346.
13. Abonour R, Williams DA, Einhorn L, et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med. 2000;6:652-658.
14. Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1:1017-1023.
15. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998;4:775-780.
16. Bodine DM, Seidel NE, Gale MS, Nienhuis AW, Orlic D. Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor. Blood. 1994;84:1482-1491.
17. Dunbar CE, Seidel NE, Doren S, et al. Improved retroviral gene transfer into murine and rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc Natl Acad Sci U S A. 1996;93:11871-11876.
18. Briddell RA, Hartley CA, Smith KA, McNiece IK. Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood. 1993;82:1720-1723.
19. Yan XQ, Briddell R, Hartley C, Stoney G, Samal B, McNiece I. Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood. 1994;84:795-799.
20. Yan XQ, Hartley C, McElroy P, Chang A, McCrea C, McNiece I. Peripheral blood progenitor cells mobilized by recombinant granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice. Blood. 1995;85:2303-2307.
21. de Revel T, Appelbaum FR, Storb R, et al. Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood. 1994;83:3795-3799.
22. Andrews RG, Bensinger WI, Knitter GH, et al. The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons. Blood. 1992;80:2715-2720.
23. Andrews RG, Briddell RA, Knitter GH, et al. In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells. Blood. 1994;84:800-810.
24. Andrews RG, Briddell RA, Knitter GH, Rowley SD, Appelbaum FR, McNiece IK. Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood. 1995;85:15-20.
25. Donahue RE, Kirby MR, Metzger ME, Agricola BA, Sellers SE, Cullis HM. Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor. Blood. 1996;87:1644-1653.
26. Moskowitz CH, Stiff P, Gordon MS, et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's patients - results of a phase I/II trial. Blood. 1997; 89:3136-3147.
27. Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997;90:2939-2951.
28. Shpall EJ, Wheeler CW, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and Filigrastim in patients with high-risk breast cancer. Blood. 1999;93:2491-2501.
29. Weaver A, Change J, Wrigley E, et al. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol. 1998;16:2601-2602.
30. Facon T, Harousseau JL, Maloisel F, et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood. 1999;94:1218-1225.
31. Lyman SD, Jacobsen SEW. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood. 1998;91:1101-1134.
32. Sudo Y, Shimazaki C, Ashihara E, et al. Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood. 1997;89:3186-3191.
33. Papayannopoulou T, Nakamoto B, Andrews RG, Lyman SD, Lee MY, In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood. 1997;90:620-629.
34. Rosenzweig M, MacVittie TJ, Harper D, et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 1999;94:2271-2286.
35. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol. 1986; 6:2895-2902.
36. Cassel A, Cottler-Fox M, Doren S, Dunbar CE. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol. 1993;21:585-591.
37. Shi PA, Pomper GJ, Metzger ME, Donahue RE, Leitman SF, Dunbar CE. Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models. Transfusion. 2001;41:1438-1444.
38. Tisdale JF, Hanazono Y, Sellers SE, et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998;92:1131-1141.
39. Takatoku M, Sellers S, Agricola BA, et al. Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. J Clin Invest. 2001;108:447-455.
40. Kluge KA, Bonifacino AC, Sellers S, Agricola BA, Donahue RE, Dunbar CE. Retroviral transduction and engraftment ability of primate hematopoietic progenitor and stern cells transduced under serum-free versus serum-containing conditions. Mol Ther. 2002;5:316-322.
41. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood. 1996;88:3323-3328.
42. Hess DA, Levac KD, Karanu FN, et al. Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. Blood. 2002;100:869-878.
43. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10:4239-4242.
44. Roe T-Y, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 1993;12:2099-2108.
45. Hajihosseini M, lavachev L, Price J. Evidence that retroviruses integrate into post-replication host DNA. EMBO J. 1993;12:4969-4974.
46. Gothot A, van der Loo JCM, Clapp DW, Srour EF. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34+ cells in non-obese diabetic/severe combined immune-deficient mice. Blood. 1998;92:2641-2649.
47. Kittler EL, Peters SO, Crittenden RB, et al. Cytokine-facilitated transduction leads to low-level engraftment in nonablated hosts. Blood. 1997;90:865-872.
48. Dorrell C, Gan OI, Pereira DS, Hawlet RG, Dick JE. Expansion of human cord blood CD34+CD38-cells in ex vivo culture dudng retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. Blood. 2000;95:102-110.
49. Dao MA, Hannum CH, Kohn DB, Nolta JA. FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. Blood. 1997;89:446-456.
50. Duarte RF, Frank DA. SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. Blood. 2000;96:3422-3430.
51. Szilvassy SJ, Meyerrose TE, Ragland PL, Grimes B. Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver. Blood. 2001;98:2108-2115.
52. Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ. Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol. 1995;23:461-466.
53. Traycoff CM, Cornetta K, Yoder MC, Davidson A, Srour EF. Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells processing different levels of bone marrow repopulating potential. Exp Hematol. 1996;24:299-306.
54. Habibian HK, Peters SO, Hsieh CC, et al. The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J Exp Med. 1998;188:393-398.
55. Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci U S A. 1996;93:11097-11102.
56. Orlic D, Girard LJ, Anderson SM, et al. Identification of human and mouse hematopoietic stem cell populations expressing high levels of mRNA encoding retrovirus receptors. Blood. 1998;91:3247-3254.